David Perz
Family Medicine · Hemet, CANPI 1558450684
Payments from drug & device makers
Across 500 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AbbVie$1K
- AstraZeneca$846
- Corcept Therapeutics$676
- Amgen$574
- Johnson & Johnson$479
- plus $4K from 38 others
What the payments were for
- Consulting fees$1,20012%
- Travel & lodging$3333%
- Food & beverage$8,34483%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,007 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 25 | $509,815 |
| OzempicSemaglutide | 165 | $157,122 |
| FarxigaDapagliflozin Propanediol | 112 | $81,939 |
| XareltoRivaroxaban | 122 | $72,936 |
| JardianceEmpagliflozin | 75 | $70,414 |
| EliquisApixaban | 84 | $66,897 |
| Glatiramer Acetate | 12 | $64,305 |
| JanuviaSitagliptin Phosphate | 74 | $55,232 |
| TrulicityDulaglutide | 48 | $52,340 |
| EntrestoSacubitril/Valsartan | 42 | $40,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $39,705 |
| MounjaroTirzepatide | 21 | $28,888 |
| VraylarCariprazine Hcl | 17 | $24,005 |
| KerendiaFinerenone | 24 | $19,397 |
| MyrbetriqMirabegron | 28 | $15,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $676 | $509,81525 claims |
| Novo NordiskOzempic | $175 | $157,122165 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $846 | $100,572146 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $234 | $90,552114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $114 | $81,22869 claims |
| MerckJanuvia, Verquvo, Belsomra | $281 | $75,041108 claims |
| Johnson & JohnsonXarelto | $479 | $72,936122 claims |
| PfizerEliquis | $248 | $66,89784 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $227 | $46,96255 claims |
| NovartisEntresto | $139 | $40,51442 claims |
| AbbVieVraylar, Creon | $1,115 | $37,84635 claims |
| BayerKerendia | $270 | $19,39724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Hemet
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.